We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

EGFR, HER2 & Receptor Tyrosine Kinases

Receptor tyrosine kinase antibodies bind growth factor receptors such as epidermal growth factor receptor (EGFR). Cetuximab, panitumumab and necitumumab block ligand binding to EGFR, and amivantamab binds both EGFR and the MET receptor. Trastuzumab, pertuzumab and margetuximab bind distinct epitopes of the HER2 receptor, and patritumab targets HER3 on tumor cells. Teprotumumab binds insulin-like growth factor 1 receptor (IGF-1R), and onartuzumab is a one-armed antibody against MET. Further antibodies target fibroblast growth factor receptors, AXL, EphA2, KIT and protein tyrosine kinase 7 (PTK7).

1 Item

  • Cofetuzumab pelidotin
    Cat. No.
    A41727
    CAS No.
    1869937-48-3

    Cofetuzumab pelidotin

    Synonyms: PF-06647020; ABBV-647; h6M24-vc0101

    Cofetuzumab pelidotin is a targeted antibody-drug conjugate (ADC) that inhibits PTK7, consisting of a humanized anti-PTK7 monoclonal antibody and an auristatin microtubule inhibitor payload linked by a cleavable valine-citrulline linker. With a drug-to-antibody ratio (DAR) of 4, it demonstrates binding to cell-surface PTK7 with an EC50 of 1153 pM as evidenced by flow cytometry. Cofetuzumab pelidotin exhibits potential effectiveness in the research of solid tumors, enabling exploration of novel therapeutic strategies.

    In stock View Details
    1 mg
    $520.00
    5 mg
    $1,395.00
    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...